Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of 8.08% and Operating profit at 0.31% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 11.11% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 8.08% and Operating profit at 0.31% over the last 5 years
3
With a fall in Net Sales of -9.19%, the company declared Very Negative results in Mar 25
4
With ROE of 7.38%, it has a expensive valuation with a 3.19 Price to Book Value
5
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 31,565 Million (Large Cap)
43.00
NA
1.15%
0.62
7.38%
3.19
Revenue and Profits:
Net Sales:
2,121 Million
(Quarterly Results - Jun 2025)
Net Profit:
109 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-32.05%
0%
-32.05%
6 Months
-3.23%
0%
-3.23%
1 Year
-0.66%
0%
-0.66%
2 Years
16.6%
0%
16.6%
3 Years
-9.87%
0%
-9.87%
4 Years
-14.09%
0%
-14.09%
5 Years
-48.3%
0%
-48.3%
Zhejiang Huahai Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.08%
EBIT Growth (5y)
0.31%
EBIT to Interest (avg)
6.41
Debt to EBITDA (avg)
2.72
Net Debt to Equity (avg)
0.60
Sales to Capital Employed (avg)
0.54
Tax Ratio
22.54%
Dividend Payout Ratio
32.47%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.81%
ROE (avg)
11.11%
Valuation key factors
Factor
Value
P/E Ratio
43
Industry P/E
Price to Book Value
3.19
EV to EBIT
35.00
EV to EBITDA
18.38
EV to Capital Employed
2.35
EV to Sales
4.28
PEG Ratio
NA
Dividend Yield
1.15%
ROCE (Latest)
6.71%
ROE (Latest)
7.38%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
2,121.30
2,336.10
-9.19%
Operating Profit (PBDIT) excl Other Income
410.20
631.50
-35.04%
Interest
59.40
56.90
4.39%
Exceptional Items
19.40
13.30
45.86%
Consolidate Net Profit
109.10
296.00
-63.14%
Operating Profit Margin (Excl OI)
76.40%
164.10%
-8.77%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -9.19% vs 2.98% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -63.14% vs 321.65% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
9,430.60
8,212.00
14.84%
Operating Profit (PBDIT) excl Other Income
2,489.30
2,082.60
19.53%
Interest
226.10
237.80
-4.92%
Exceptional Items
-83.30
-126.70
34.25%
Consolidate Net Profit
1,107.50
817.20
35.52%
Operating Profit Margin (Excl OI)
165.10%
157.50%
0.76%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 14.84% vs 0.28% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 35.52% vs -30.51% in Dec 2023
About Zhejiang Huahai Pharmaceutical Co., Ltd. 
Zhejiang Huahai Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






